Prospective evaluation of the safety of transrectal ultrasound-guided transperineal prostate biopsy based on adverse events
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605490619 | ||
| 003 | CHVBK | ||
| 005 | 20210128100505.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20151201xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10147-015-0831-6 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10147-015-0831-6 | ||
| 245 | 0 | 0 | |a Prospective evaluation of the safety of transrectal ultrasound-guided transperineal prostate biopsy based on adverse events |h [Elektronische Daten] |c [Takeshi Namekawa, Satoshi Fukasawa, Atsushi Komaru, Masayuki Kobayashi, Yusuke Imamura, Takayuki Ohzeki, Kimiaki Takagi, Yosuke Sato, Koichiro Akakura, Tomohiko Ichikawa, Takeshi Ueda] |
| 520 | 3 | |a Background: Although transperineal (TP) prostate biopsy is growing in popularity, its safety has not been evaluated based on extensive studies. We prospectively assessed the adverse events associated with transrectal ultrasound (TRUS)-guided TP 16-core prostate biopsy at a single institution. Patients and methods: We enrolled 2,086 males who underwent first-time TRUS-guided TP prostate biopsy under lumbar spinal anesthesia at Chiba Cancer Center between 2009 and 2013. Eight adverse events were assessed prospectively using a purpose-designed questionnaire. The prevalence and duration of all adverse events were evaluated. We performed subgroup analyses for hematuria and urinary retention in relation to clinical factors. Results: Questionnaires were collected from 1,663 cases (79.7%). The cancer detection rate was 53.5% in all patients. The prevalence and duration of complications were as follows: hematuria, 73.4% and 4.51±2.88days; perineal bleeding, 7.1% and 2.20±2.24days; hematospermia 14.4%; dysuria, 15.7% and 3.12±2.71days; urinary tract pain, 49.5% and 2.43±2.08days; perineal pain, 35.5% and 3.53±2.59days; fever ≥37°C, 1.7% and 1.79±1.72days; and headache, 22.1% and 3.40±2.10days. Seventeen patients (1.1%) required indwelling urethral catheterization for grade 2 urinary retention. Pre-biopsy International Prostate Symptom Score (p=0.014) was an independent related factor for hematuria. Prostate volume (p=0.001) was an independent related factor for grade 2 urinary retention. Conclusions: TRUS-guided TP prostate biopsy under lumbar spinal anesthesia can be performed safely with only minor adverse events. | |
| 540 | |a Japan Society of Clinical Oncology, 2015 | ||
| 690 | 7 | |a Adverse events |2 nationallicence | |
| 690 | 7 | |a Prostate cancer |2 nationallicence | |
| 690 | 7 | |a Transperineal biopsy |2 nationallicence | |
| 690 | 7 | |a Questionnaire |2 nationallicence | |
| 700 | 1 | |a Namekawa |D Takeshi |u Prostate Center and Division of Urology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, 260-8717, Chiba, Chiba, Japan |4 aut | |
| 700 | 1 | |a Fukasawa |D Satoshi |u Prostate Center and Division of Urology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, 260-8717, Chiba, Chiba, Japan |4 aut | |
| 700 | 1 | |a Komaru |D Atsushi |u Prostate Center and Division of Urology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, 260-8717, Chiba, Chiba, Japan |4 aut | |
| 700 | 1 | |a Kobayashi |D Masayuki |u Prostate Center and Division of Urology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, 260-8717, Chiba, Chiba, Japan |4 aut | |
| 700 | 1 | |a Imamura |D Yusuke |u Prostate Center and Division of Urology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, 260-8717, Chiba, Chiba, Japan |4 aut | |
| 700 | 1 | |a Ohzeki |D Takayuki |u Prostate Center and Division of Urology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, 260-8717, Chiba, Chiba, Japan |4 aut | |
| 700 | 1 | |a Takagi |D Kimiaki |u Prostate Center and Division of Urology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, 260-8717, Chiba, Chiba, Japan |4 aut | |
| 700 | 1 | |a Sato |D Yosuke |u Prostate Center and Division of Urology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, 260-8717, Chiba, Chiba, Japan |4 aut | |
| 700 | 1 | |a Akakura |D Koichiro |u Division of Urology, Japan Community Health Care Organization, Tokyo Shinjuku Medical Center, Tokyo, Japan |4 aut | |
| 700 | 1 | |a Ichikawa |D Tomohiko |u Department of Urology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana-cho, Chuo-ku, 260-8670, Chiba, Japan |4 aut | |
| 700 | 1 | |a Ueda |D Takeshi |u Prostate Center and Division of Urology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, 260-8717, Chiba, Chiba, Japan |4 aut | |
| 773 | 0 | |t International Journal of Clinical Oncology |d Springer Japan |g 20/6(2015-12-01), 1185-1191 |x 1341-9625 |q 20:6<1185 |1 2015 |2 20 |o 10147 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10147-015-0831-6 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10147-015-0831-6 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Namekawa |D Takeshi |u Prostate Center and Division of Urology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, 260-8717, Chiba, Chiba, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Fukasawa |D Satoshi |u Prostate Center and Division of Urology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, 260-8717, Chiba, Chiba, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Komaru |D Atsushi |u Prostate Center and Division of Urology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, 260-8717, Chiba, Chiba, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Kobayashi |D Masayuki |u Prostate Center and Division of Urology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, 260-8717, Chiba, Chiba, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Imamura |D Yusuke |u Prostate Center and Division of Urology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, 260-8717, Chiba, Chiba, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Ohzeki |D Takayuki |u Prostate Center and Division of Urology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, 260-8717, Chiba, Chiba, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Takagi |D Kimiaki |u Prostate Center and Division of Urology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, 260-8717, Chiba, Chiba, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Sato |D Yosuke |u Prostate Center and Division of Urology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, 260-8717, Chiba, Chiba, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Akakura |D Koichiro |u Division of Urology, Japan Community Health Care Organization, Tokyo Shinjuku Medical Center, Tokyo, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Ichikawa |D Tomohiko |u Department of Urology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana-cho, Chuo-ku, 260-8670, Chiba, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Ueda |D Takeshi |u Prostate Center and Division of Urology, Chiba Cancer Center, 666-2 Nitona-cho, Chuo-ku, 260-8717, Chiba, Chiba, Japan |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t International Journal of Clinical Oncology |d Springer Japan |g 20/6(2015-12-01), 1185-1191 |x 1341-9625 |q 20:6<1185 |1 2015 |2 20 |o 10147 | ||